Additional Relevant Details Secondary endpoints showed significant difference in improvement from baseline for SAGE-547 compared to placebo over three weeks following end of treatmentData are consistent with previously reported top-line results, including primary endpoint achieved with statistical significance at 60 hours and maintained through 30 daysPursuing publication of comprehensive dataset in a peer-reviewed journalCurrently dosing patients with moderate or severe PPD in separate placebo-controlled trials; top-line data expected in 2017Breakthrough Therapy Designation recently granted by FDA for treatment of postpartum depression; near-term meeting with FDA planned to discuss development pathway